The Evolving Role of the Sales Rep
June 29, 2022 | COVID-19, MSL, Medical science liaison, Pharma, Sales, sales representative, training
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in a digital world.
Traditionally, the foundation of pharmaceutical sales has been in-person visits between sales representatives and healthcare professionals (HCPs), which include events, conferences, dinners, and in-office visits. However, during the COVID-19 pandemic, this came to a grounding halt—all face-to-face visits were canceled, and reps had to find new ways to engage HCPs.
As a result, meetings took place online, through Teams and Zoom, and engagements became more digital. Two years since the start of the pandemic, HCPs have shown a preference for digital communications, and now, biopharma companies are re-evaluating the role of the sales representative altogether. According to a trends report by MM+M, 29% of biopharma companies are cutting back on rep spending while almost 50% are increasing their spend on engaging HCPs.
What does this shift look like for the role of the sales rep moving forward? Is there still a need for sales reps to pound the pavement with HCPs and focus on getting out more product? Or is it better to have a smaller, centralized sales team that focuses on fostering strong relationships and improving education and patient care?
How the Role of the Sales Rep Has Changed in the New COVID Era
In a recent conversation with Jill Padgett, EdD, Head of Training, she explains how today, “sales representatives are engaging with more customers who do not have an MD behind their name such as the Reimbursement Specialist, Practice Manager, Nurse and Patient Educators, etc., as they do with HCPs.”
This means that a sales force must be just as well-versed in building relationships with payers and other nonphysician customers as they are with traditional doctors. Sales representatives still have immense value for biopharmaceutical companies, but in a new COVID era, they can play a key role in helping HCPs navigate the complex and evolving pharmaceutical landscape by being better armed with digital communications, tools, and analytics that can provide an extra layer of support and personalization.
“The impact of the pandemic has made significant changes,” says Jill. “For example, it has been said that as a result of the pandemic, the use of digital technology has been accelerated by 6 years. Biopharma industries feel that acceleration in the way HCP engagement has changed. Some HCPs realize that they like fewer interruptions from sales representatives and they limit their contacts. In fact, research by Veeva shows that access to HCPs dropped by 57% in 2021. Others predict that a new HCP engagement norm may shift from in-person to digital by as much as 80% digital vs 20% in-person.”
Jill believes that this change brings about the need for biopharma reps to reskill in 2 critical areas.
This content was provided by Avalere Health
Company Details
Latest Content from Avalere Health
Avalere Health appoints new President of Medical to lead a tech-enabled future of medical affairs
Avalere Health appoints seasoned industry executive Effie Baoutis as President of Medical.
Fishawack Health becomes Avalere Health, uncovering the potential in every product and the possibilities for every patient
As a single united organization, the company seamlessly connects science and creativity, technology and data, and ability and agility to ensure patients receive life-changing innovations faster.
Industry leader Amar Urhekar joins Fishawack Health as Chief Operating Officer to integrate interdisciplinary teams across capabilities
As Chief Operating Officer, Amar will unite global teams to drive innovation, enhance client solutions, and accelerate growth.
Fishawack Health appoints Chief People Officer to spearhead integration of talent and culture across geographies
Fishawack Health welcomes Harriet Shurville to the team as Chief People Officer to spearhead integration efforts, champion diversity and inclusion, and cultivate an environment where interdisciplinary teams thrive.
Archetypes: Rethinking go-to-market expectations to drive commercial success
In this white paper, our consultants analyze trends spanning global policy developments, rising inflation, and increasingly complex customer journeys, and reveal a new data-driven approach to archetyping that crystalizes the...
Fishawack Health deepens key capabilities and builds an integrated delivery model under new Chief Marketing and Creative Officer
Polymath marketer Ryan Mason leads the newly expanded group, and Jeffrey D. Erb has been tapped to grow the media and analytics team as Chief Media Officer.
Oncology eBook: Reducing the care gap in cancer prevention, diagnosis, and treatment
Despite significant innovation in the oncology landscape, there is a growing care gap preventing patients accessing and benefiting from innovations in cancer treatment. In this new publication, our oncology experts...
The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech...
Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.